/MEDS
MEDS Stock - TRxADE HEALTH, Inc.
Healthcare|Medical - PharmaceuticalsNASDAQ
$7.59+4.55%
+$0.33 (+4.55%) • Sep 20
48
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.29
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.33
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $8.35
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MEDS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.51 – $7.67
TARGET (TP)$8.73
STOP LOSS$6.98
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.17
52W High$44.56
52W Low$3.69
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $136,643 | $8.27M | $11.45M | $9.89M | $17.12M |
| Gross Profit | $6,005 | $2.60M | $5.45M | $4.75M | $5.71M |
| Gross Margin | 4.4% | 31.4% | 47.6% | 48.0% | 33.3% |
| Operating Income | $-18,778,876 | $-7,263,406 | $-2,756,545 | $-5,292,293 | $-1,780,689 |
| Net Income | $9.07M | $-17,843,574 | $-4,310,205 | $-4,113,047 | $-2,565,440 |
| Net Margin | 6634.7% | -215.7% | -37.6% | -41.6% | -15.0% |
| EPS | $2.69 | $-23.35 | $-7.63 | $-7.58 | $-4.99 |
Company Overview
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
MEDSBeat Rate
20%
Last 15 quarters
Avg Surprise
-1036.2%
EPS vs Estimate
Beats / Misses
3/12
Last 12 quarters
Latest EPS
$-0.19
Q4 2025
EPS Surprise History
Q2 24
-8281.6%
$-12.57vs$-0.15
Q2 24
-4166.7%
$-6.40vs$-0.15
Q3 24
-593.3%
$-1.04vs$-0.15
Q1 25
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 12, 2025 | — | $-0.19 | — | — |
Q3 2025 | Aug 7, 2025 | — | $-0.48 | — | — |
Q2 2025 | Jun 24, 2025 | — | $-0.65 | — | — |
Q1 2025 | Mar 26, 2025 | — | $-2.01 | — | — |
Q1 2025 | Jan 14, 2025 | — | $-1.34 | — | — |
Q3 2024 | Aug 9, 2024 | $-0.15 | $-1.04 | -593.3% | ✗ MISS |
Q2 2024 | Jun 26, 2024 | $-0.15 | $-6.40 | -4166.7% | ✗ MISS |
Q2 2024 | Apr 22, 2024 | $-0.15 | $-12.57 | -8281.6% | ✗ MISS |
Q1 2024 | Jan 16, 2024 | $-0.15 | $-0.07 | +53.3% | ✓ BEAT |
Q3 2023 | Aug 18, 2023 | $-0.75 | $-0.77 | -2.7% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.30 | $-0.45 | -50.0% | ✗ MISS |
Q1 2023 | Mar 27, 2023 | $-0.90 | $-1.50 | -66.7% | ✗ MISS |
Q4 2022 | Nov 7, 2022 | $-1.80 | $-0.90 | +50.0% | ✓ BEAT |
Q3 2022 | Jul 25, 2022 | $-1.35 | $-1.95 | -44.4% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-1.35 | $-1.80 | -33.3% | ✗ MISS |
Q1 2022 | Mar 28, 2022 | $-1.80 | $-1.35 | +25.0% | ✓ BEAT |
Q4 2021 | Oct 25, 2021 | $-0.13 | $-0.16 | -23.1% | ✗ MISS |
Q3 2021 | Jul 26, 2021 | $-1.05 | $-2.55 | -142.9% | ✗ MISS |
Q2 2021 | Apr 26, 2021 | $-0.45 | $-1.20 | -166.7% | ✗ MISS |
Q1 2021 | Mar 29, 2021 | $-0.01 | $-0.20 | -2100.2% | ✗ MISS |
Latest News
SCNX stock has given up its prior gain. Scienture Holdings shares were trading higher after the company announced a strategic collaboration with Blink Rx to expand national access to Arbli.
➖ NeutralBenzinga•Dec 10, 2025, 04:22 PM•Also:
Scienture Holdings shares are trading higher after the company announced a strategic collaboration with Blink Rx to expand national access to Arbli.
📈 PositiveBenzinga•Dec 10, 2025, 01:08 PM•Also:
SCIENTURE HOLDINGS Collaborates With BlinkRx For Expanded Patient Access To Arbli.
📈 PositiveBenzinga•Dec 10, 2025, 01:07 PM•Also:
Scienture Holdings Q3 EPS $(0.19) Up From $(1.34) YoY, Sales $590.050K Up From $64.861K YoY
📈 PositiveBenzinga•Nov 13, 2025, 01:21 PM•Also:
Scienture Holdings, Inc. shares are trading higher after the company announced that Arbli (losartan potassium) oral suspension was added to key national payor formularies, expanding commercial and Medicare coverage.
📈 PositiveBenzinga•Nov 4, 2025, 12:55 PM•Also:
EXCLUSIVE: SCIENTURE HOLDINGS Tells Benzinga 'Arbli Oral Suspension, 10 mg/mL has been added to the formularies of key national payors, expanding access through both multiple commercial coverage and Medicare supplement plans'
📈 PositiveBenzinga•Nov 4, 2025, 12:50 PM•Also:
EXCLUSIVE: SCIENTURE HOLDINGS Tells Benzinga Co. Announces Addition Of Arbli To Formularies Of Major National Health Plans, Says 'Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide'
📈 PositiveBenzinga•Nov 4, 2025, 12:50 PM•Also:
Scienture Holdings Shares Halted On Circuit Breaker To The Upside, Stock Now Up 354.94%
📈 PositiveBenzinga•Oct 23, 2025, 07:46 PM•Also:
Scienture Holdings Shares Resume Trading, Halted Again On Circuit Breaker; Up 137%
📈 PositiveBenzinga•Oct 23, 2025, 03:17 PM•Also:
Scienture Holdings Shares Halted On Circuit Breaker To The Upside, Stock Now Up 183.46%
📈 PositiveBenzinga•Oct 23, 2025, 03:05 PM•Also:
EXCLUSIVE: SCIENTURE HOLDINGS Tells Benzinga 'Company launches multi-channel promotional campaign to drive market adoption'
📈 PositiveBenzinga•Oct 23, 2025, 11:50 AM•Also:
EXCLUSIVE: SCIENTURE HOLDINGS Tells Benzinga Co. Announces Start Of Commercial Sales And Fulfillment Of First Orders For Arbli
📈 PositiveBenzinga•Oct 23, 2025, 11:50 AM•Also:
SCIENTURE HOLDINGS Says Arbli Oral Suspension, 10mg/mL, Is Commercially Available Through Full-Line Wholesalers Nationwide
📈 PositiveBenzinga•Oct 16, 2025, 01:04 PM•Also:
Scienture Holdings Settles All Outstanding Debentures With Arena Investors Via Share Conversion At $2.4861/Share
➖ NeutralBenzinga•Oct 8, 2025, 01:08 PM•Also:
EXCLUSIVE: SCIENTURE HOLDINGS Tells Benzinga 'Represents potential penetration into ~ 20% of the U.S. institutional market, while broadening access across long-term care and outpatient facilities'
📈 PositiveBenzinga•Oct 1, 2025, 12:45 PM•Also:
EXCLUSIVE: SCIENTURE HOLDINGS Tells Benzinga Co. Secures Multiple Commercial GPO Agreements, Says Expanding US Market Access For Arbli To More Than 2500 Healthcare Institutions
📈 PositiveBenzinga•Oct 1, 2025, 12:45 PM•Also:
Scienture Holdings May Offer & Sell Shares Of Common Stock Of Up To $9.2M From Time To Time
➖ NeutralBenzinga•Sep 19, 2025, 09:54 PM•Also:
Frequently Asked Questions about MEDS
What is MEDS's current stock price?
TRxADE HEALTH, Inc. (MEDS) is currently trading at $7.59 per share. The stock has moved +4.55% today.
What is the analyst price target for MEDS?
No analyst price targets are currently available for this stock.
What sector is TRxADE HEALTH, Inc. in?
TRxADE HEALTH, Inc. operates in the Healthcare sector, specifically within the Medical - Pharmaceuticals industry. The company is traded on the NASDAQ exchange.
What is MEDS's market cap?
TRxADE HEALTH, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does MEDS pay dividends?
No, TRxADE HEALTH, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAXLA
Axcella Health Inc.
$4.58
Mkt Cap: $0.0B
BBLNF
Babylon Holdings Limited
$0.00
Mkt Cap: $0.0B
CANO
Cano Health, Inc.
$2.30
Mkt Cap: $0.0B
CJJD
China Jo-Jo Drugstores, Inc.
$1.52
Mkt Cap: $0.0B
CYAD
Celyad Oncology S.A.
$0.47
Mkt Cap: $0.0B
DOLE
Dole plc
$15.27
Mkt Cap: $1.5B
ME
23andMe Holding Co.
$0.61
Mkt Cap: $0.0B
REUN
Reunion Neuroscience Inc.
$1.12
Mkt Cap: $0.0B
SQZB
SQZ Biotechnologies Company
$0.02
Mkt Cap: $0.0B
TLPH
Talphera, Inc.
$1.10
Mkt Cap: $0.0B
Explore stocks similar to MEDS for comparison